Ocugen (OCGN) Reports Q1 Loss of $0.04/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ocugen Provides Business Update and First Quarter 2021 Financial Results
May 7, 2021 7:30 AM EDTConference Call and Webcast Today at 8:30 a.m. ET
COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization)Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency Use Authorization application for COVAXIN$100.0Â million in gross proceeds raised through a registered direct offering of common stockKey talent acquired representing an instrumental step to position Ocugen for future growthMALVERN, Pa., May 07, 2021 (GLOBE... More
